Canaccord Genuity restated their buy rating on shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) in a report published on Wednesday, The Fly reports. They currently have a $65.00 target price on the stock, up from their prior target price of $50.00.

DCPH has been the subject of a number of other reports. BidaskClub raised shares of Deciphera Pharmaceuticals from a strong sell rating to a sell rating in a research note on Friday, August 2nd. ValuEngine cut shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 13th. Piper Jaffray Companies lifted their price target on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an overweight rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 price target for the company in a research note on Monday, August 5th. Finally, Guggenheim lifted their price target on shares of Deciphera Pharmaceuticals from $44.00 to $66.00 and gave the stock a buy rating in a research note on Tuesday, August 13th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $47.90.

DCPH stock opened at $37.00 on Wednesday. Deciphera Pharmaceuticals has a 12 month low of $18.55 and a 12 month high of $42.99. The company has a quick ratio of 7.26, a current ratio of 7.26 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $23.38 and a 200 day moving average price of $24.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.56. The firm had revenue of $25.00 million for the quarter, compared to analysts’ expectations of $20.00 million. As a group, research analysts forecast that Deciphera Pharmaceuticals will post -4.19 earnings per share for the current fiscal year.

In related news, CFO Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $25.06, for a total transaction of $36,913.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Daniel Lee Flynn sold 148,107 shares of Deciphera Pharmaceuticals stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $40.92, for a total transaction of $6,060,538.44. The disclosure for this sale can be found here. Insiders have sold a total of 185,607 shares of company stock valued at $7,536,409 in the last quarter. 7.02% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in shares of Deciphera Pharmaceuticals by 25.6% in the 2nd quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock valued at $34,543,000 after purchasing an additional 311,870 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Deciphera Pharmaceuticals by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 792,654 shares of the company’s stock valued at $17,874,000 after purchasing an additional 20,252 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Deciphera Pharmaceuticals by 2.1% in the 2nd quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock valued at $15,237,000 after purchasing an additional 14,028 shares in the last quarter. Norges Bank bought a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter valued at about $6,974,000. Finally, Eversept Partners LP raised its holdings in shares of Deciphera Pharmaceuticals by 21.9% in the 2nd quarter. Eversept Partners LP now owns 305,233 shares of the company’s stock valued at $6,883,000 after purchasing an additional 54,801 shares in the last quarter. Institutional investors own 59.10% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Article: Strike Price

The Fly

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.